Literature DB >> 12214011

Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease.

George Perry1, Rudy J. Castellani, Keisuke Hirai, Mark A. Smith.   

Abstract

The two most striking features of Alzheimer disease are (i) the multitude of abnormalities affecting essentially every system and (ii) the strict age dependence. Recent work suggests that both features are linked to increased oxidative stress that damages lipids, proteins and nucleic acids and results in redox-active metal accumulations, mitochondrial damage and formation of advanced glycation endproducts. Interestingly, beta-protein precursor, amyloid-beta, presenilins, and apolipoprotein E have all been linked to reactive oxygen species production or apoptosis, a process intimately associated with oxidative stress. In therapeutics, the commonality between a number of efficacious agents appears to be oxidative stress reduction. Therefore, we contend that oxidative stress is the element that links the multitude of changes in Alzheimer disease and that a reduction of oxidative stress will have a dramatic effect on reducing the incidence or progression of Alzheimer disease.

Entities:  

Year:  1998        PMID: 12214011     DOI: 10.3233/jad-1998-1103

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  52 in total

1.  Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover.

Authors:  Xiongwei Zhu; Rudy J Castellani; Paula I Moreira; Gjumrakch Aliev; Justin C Shenk; Sandra L Siedlak; Peggy L R Harris; Hisashi Fujioka; Lawrence M Sayre; Pamela A Szweda; Luke I Szweda; Mark A Smith; George Perry
Journal:  Free Radic Biol Med       Date:  2011-11-12       Impact factor: 7.376

2.  Antiradical capacity of ommochromes.

Authors:  Yanet Romero; Ana Martínez
Journal:  J Mol Model       Date:  2015-08-04       Impact factor: 1.810

3.  Effects of symptomatic and asymptomatic isolates of Blastocystis hominis on colorectal cancer cell line, HCT116.

Authors:  Kok Hoe Chan; Samudi Chandramathi; Kumar Suresh; Kek Heng Chua; Umah Rani Kuppusamy
Journal:  Parasitol Res       Date:  2012-01-26       Impact factor: 2.289

Review 4.  Indices of metabolic dysfunction and oxidative stress.

Authors:  Gemma Casadesus; Paula I Moreira; Akihiko Nunomura; Sandra L Siedlak; William Bligh-Glover; Elizabeth Balraj; Grace Petot; Mark A Smith; George Perry
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

5.  Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease.

Authors:  Gang Liu; Ping Men; Wataru Kudo; George Perry; Mark A Smith
Journal:  Neurosci Lett       Date:  2009-03-25       Impact factor: 3.046

Review 6.  Intersection between metabolic dysfunction, high fat diet consumption, and brain aging.

Authors:  Romina M Uranga; Annadora J Bruce-Keller; Christopher D Morrison; Sun Ok Fernandez-Kim; Philip J Ebenezer; Le Zhang; Kalavathi Dasuri; Jeffrey N Keller
Journal:  J Neurochem       Date:  2010-05-06       Impact factor: 5.372

7.  Nanoparticle and iron chelators as a potential novel Alzheimer therapy.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  Methods Mol Biol       Date:  2010

Review 8.  Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies.

Authors:  Michael W Marlatt; Paul J Lucassen; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 9.  Antioxidant therapy in Alzheimer's disease: theory and practice.

Authors:  Gjumrakch Aliev; Mark E Obrenovich; V Prakash Reddy; Justin C Shenk; Paula I Moreira; Akihiko Nunomura; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Mini Rev Med Chem       Date:  2008-11       Impact factor: 3.862

10.  Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  J Nanoneurosci       Date:  2009-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.